Research Analysts’ Upgrades for July 13th (ALB, AXP, BIIB, CARE, CASY, CEPL, FTRE, KEYS, SAIA, VRAX)

Research Analysts’ upgrades for Monday, July 13th:

Albemarle (NYSE:ALB) was upgraded by analysts at Wall Street Zen from a buy rating to a strong-buy rating.

American Express (NYSE:AXP) was upgraded by analysts at JPMorgan Chase & Co. from a neutral rating to an overweight rating. The firm currently has $400.00 price target on the stock, up from their previous price target of $328.00.

Biogen (NASDAQ:BIIB) was upgraded by analysts at Truist Financial Corporation from a hold rating to a buy rating. The firm currently has $235.00 price target on the stock, up from their previous price target of $190.00.

Carter Bankshares (NASDAQ:CARE) was upgraded by analysts at Wall Street Zen from a hold rating to a buy rating.

Casey’s General Stores (NASDAQ:CASY) was upgraded by analysts at Northcoast Research from a neutral rating to a buy rating. Northcoast Research currently has $950.00 target price on the stock.

Capstone Energy+ (NASDAQ:CEPL) was upgraded by analysts at Wall Street Zen to a hold rating.

Fortrea (NASDAQ:FTRE) was upgraded by analysts at Wall Street Zen from a hold rating to a buy rating.

Keysight Technologies (NYSE:KEYS) was upgraded by analysts at Wall Street Zen from a buy rating to a strong-buy rating.

Saia (NASDAQ:SAIA) was upgraded by analysts at Bank of America Corporation from a neutral rating to a buy rating. They currently have $502.00 price target on the stock, up from their previous price target of $499.00.

Virax Biolabs Group (NASDAQ:VRAX) was upgraded by analysts at Wall Street Zen from a sell rating to a hold rating.

Verra Mobility (NASDAQ:VRRM) was upgraded by analysts at JPMorgan Chase & Co. from an underweight rating to a neutral rating. The firm currently has $6.00 target price on the stock, up from their previous target price of $5.00.